Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Company profile
Ticker
BDX
Exchange
Website
CEO
Mr. Thomas E. Polen Jr.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AURORA CORP, EnerJex Resources, Inc., MILLENIUM PLASTICS CORP, MILLENNIUM PLASTICS CORP
SEC CIK
Corporate docs
Subsidiaries
Accuri Cytometers, Inc. • Adaptec Medical Devices LLC • Alverix, Inc. • Bard Access Systems, Inc. • Bard Acquisition Sub, Inc. • Bard ASDI, Inc. • Bard Brachytherapy, Inc. • Bard Devices, Inc. • Bard Global Holdings I LLC • Bard Global Holdings II LLC ...
IRS number
220760120
BDX stock data
Latest filings (excl ownership)
8-K
BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation
2 Oct 24
8-K
Departure of Directors or Certain Officers
30 Aug 24
10-Q
2024 Q3
Quarterly report
1 Aug 24
8-K
BD Reports Third Quarter Fiscal 2024 Financial Results
1 Aug 24
8-K
Entry into a Material Definitive Agreement
12 Jul 24
CERT
Certification of approval for exchange listing
12 Jun 24
8-A12B
Registration of securities on exchange
12 Jun 24
8-K
Entry into a Material Definitive Agreement
7 Jun 24
424B2
Prospectus for primary offering
6 Jun 24
424B2
Prospectus for primary offering
6 Jun 24
Transcripts
BDX
Earnings call transcript
2024 Q3
1 Aug 24
BDX
Earnings call transcript
2024 Q2
2 May 24
BDX
Earnings call transcript
2024 Q1
1 Feb 24
BDX
Earnings call transcript
2023 Q4
9 Nov 23
BDX
Earnings call transcript
2023 Q3
3 Aug 23
BDX
Earnings call transcript
2023 Q3
3 Aug 23
BDX
Earnings call transcript
2023 Q2
4 May 23
BDX
Earnings call transcript
2023 Q1
2 Feb 23
BDX
Earnings call transcript
2022 Q4
10 Nov 22
BDX
Earnings call transcript
2022 Q3
4 Aug 22
Latest ownership filings
144
Notice of proposed sale of securities
16 Sep 24
4
Christopher DelOrefice
9 Sep 24
4
Richard Byrd
4 Sep 24
4
Christopher DelOrefice
4 Sep 24
4
Michael Feld
21 Aug 24
3
Michael Feld
21 Aug 24
4
Roland Goette
15 Aug 24
4
Christopher Ian Montague Jones
2 Aug 24
4
Carrie L Byington
2 Aug 24
4/A
Christopher Ian Montague Jones
8 Jul 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2024
87.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1549 |
Opened positions | 143 |
Closed positions | 135 |
Increased positions | 593 |
Reduced positions | 560 |
13F shares | Current |
---|---|
Total value | 53.34 tn |
Total shares | 253.46 mm |
Total puts | 649.58 k |
Total calls | 586.40 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 26.31 mm | $6.15 tn |
BLK BlackRock | 22.26 mm | $5.20 tn |
STT State Street | 13.85 mm | $3.24 tn |
MS Morgan Stanley | 11.33 mm | $2.65 tn |
T. Rowe Price | 10.74 mm | $2.51 bn |
T. Rowe Price Investment Management | 7.76 mm | $1.81 bn |
Geode Capital Management | 6.17 mm | $1.44 tn |
Generation Investment Management | 5.41 mm | $1.26 tn |
AMP Ameriprise Financial | 5.06 mm | $1.18 tn |
Massachusetts Financial Services | 4.91 mm | $1.15 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Sep 24 | Christopher DelOrefice | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 466 | 0.00 | 12,792 |
1 Sep 24 | Christopher DelOrefice | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 254 | 0.00 | 13,258 |
1 Sep 24 | Richard Byrd | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 216 | 0.00 | 6,060 |
20 Aug 24 | Michael Feld | Common Stock | Grant | Acquire A | No | No | 0 | 6,637 | 0.00 | 6,637 |
News
BD Reveals Commercial Launch Of New Robotics Solution That Will Enable Automation
14 Oct 24
BD Reaches Agreement To Resolve Vast Majority Of Its Existing Hernia Litigation, Terms Confidential; Expects Settlement Not To Change Cash Flow Goals Or Capital Allocation Strategy
2 Oct 24
Evercore ISI Group Maintains Outperform on Becton Dickinson, Raises Price Target to $290
1 Oct 24
A Glimpse Into The Expert Outlook On Becton Dickinson Through 4 Analysts
1 Oct 24
Citigroup Upgrades Becton Dickinson to Buy, Raises Price Target to $275
1 Oct 24
Press releases
BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research
14 Oct 24
BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results
10 Oct 24
BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation
2 Oct 24
New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion
26 Sep 24
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples
25 Sep 24